Holen Sie sich die Stockscreener-App
3.56
1.14%
0.04
Handel nachbörslich:
3.64
0.08
+2.25%
Schlusskurs vom Vortag:
$3.52
Offen:
$3.57
24-Stunden-Volumen:
1.71M
Relative Volume:
0.57
Marktkapitalisierung:
$393.62M
Einnahmen:
$35.95M
Nettoeinkommen (Verlust:
$-104.99M
KGV:
-2.624
EPS:
-1.3567
Netto-Cashflow:
$-99.30M
1W Leistung:
+0.00%
1M Leistung:
+15.96%
6M Leistung:
+45.90%
1J Leistung:
+159.85%
1-Tages-Spanne:
$3.54
$3.69
1-Wochen-Bereich:
$3.05
$3.69
52-Wochen-Spanne:
$1.21
$3.95
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.56 | 389.20M | 35.95M | -104.99M | -99.30M | -1.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | TD Cowen | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc. - Traders Union
C4 Therapeutics to Participate in Upcoming Conferences - Investing News Network
C4 Therapeutics to speak at TD Cowen, Jefferies, Goldman healthcare events - Stock Titan
C4 Therapeutics deepens Roche alliance to target breakthrough cancer therapies - MSN
C4 Therapeutics (NASDAQ: CCCC) — Squadron Fund reports 5.55M shares - Stock Titan
Biotech C4 Therapeutics gives new hire options on 85,480 shares - Stock Titan
C4 Therapeutics, Inc. to present new cemsidomide Phase 1 data at EHA Hematology 2026 Congress - Traders Union
C4 Therapeutics Realigns Finance Leadership After Officer Departure - The Globe and Mail
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Point72 reports 169,096-share stake in C4 Therapeutics (CCCC) as of Mar 31, 2026 - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics (NASDAQ: CCCC) names CFO as principal accountant - Stock Titan
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
C4 Therapeutics (CCCC) — Sirenia/Silverstein report 23.5M shares, near 10% stake - Stock Titan
C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns - Sahm
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biogen Inc. stock (US09062X1037): Q1 milestone payment amid partner C4 Therapeutics earnings - AD HOC NEWS
C4 Therapeutics (CCCC) Reports Strong Q1 Revenue and Clinical Ad - GuruFocus
C4 Therapeutics, Inc. (CCCC) reports Q1 loss, lags revenue estimates - MSN
CCCC Financials: Income Statement, Balance Sheet & Cash Flow | C4 Therapeutics, Inc. - Stock Titan
C4 Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Investing News Network
C4 Therapeutics Reports Q1 Results and Clinical Advancements - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
C4 Therapeutics Advances Cemsidomide for Multiple Myeloma Treatment Amid Ongoing Clinical Trials and Expanded Partnership with Roche - Quiver Quantitative
C4 Therapeutics 1Q 2026: Revenue $6.15M, EPS ($0.2) — 10-Q Summary - TradingView
C4 Therapeutics (NASDAQ: CCCC) Q1 loss, $268M cash and new Roche DAC deal - Stock Titan
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
C4 Therapeutics (NASDAQ: CCCC) Q1 loss $25.1M with $268M cash runway to 2028 - Stock Titan
Biotech behind new myeloma drug teams with Roche, holds cash to 2028 - Stock Titan
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Fulcrum hires get 55,500 stock options at $7.02 a share - Stock Titan
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
CCCC Stock Price, Quote & Chart | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):